AMLX · CIK 0001658551
What Amylyx Pharmaceuticals, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for AMLX. More may follow as additional filings are processed.
In its own words
What could break it.
Geographic concentration
- Bulk drug substances imported from Europe and Canadamedium
Relies on raw materials and bulk drug substances imported from Europe and Canada to manufacture AMX0035 and future candidates; geopolitical instability could disrupt this supply.
“The Company and its contractors may experience disruptions in supply of items that are essential for its research and development activities, including, for example, raw materials and bulk drug substances that the Company imports from Europe and Canada used in the manufacturing of AMX0035 and any additional or future product candidates.”
Liquidity & debt
- No product revenue after RELYVRIO/ALBRIOZA discontinuation; cash runway into 2028medium
Discontinued its only commercial product in 2024 and generated no product revenue in 2025; held $317.0M cash and a $751.4M accumulated deficit, with runway into 2028.
“As of December 31, 2025, we had cash, cash equivalents and marketable securities of $317.0 million and an accumulated deficit of $751.4 million. We believe our existing cash, cash equivalents and marketable securities as of December 31, 2025 will be sufficient to fund our operations into 2028.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch